Category Archives: Prevention, Engagement and Care Cascade

The efficacy of behavioral interventions in reducing HIV risk sex behaviors and incident sexually transmitted disease in black and Hispanic sexually transmitted disease clinic patients in the United States: a meta-analytic review

2007

OBJECTIVES: Interventions targeting sexually transmitted disease (STD) clinic patients provide an important opportunity to modify high-risk sex behaviors related to HIV/STD transmission. Identifying efficacious interventions for blacks and Hispanics is...

Weighing the gold in the gold standard: Challenges in HIV prevention research

2010

OBJECTIVE(S): Few HIV prevention interventions have been evaluated in randomized controlled trials (RCTs). We examined design, implementation, and contextual considerations that may limit detection of a positive or adverse effect...

Etravirine as a switching option for patients with HIV RNA suppression: A review of recent trials

2014

Unlike other nonnucleoside reverse transcriptase inhibitors, etravirine is only approved for use in treatment-experienced patients. In the DUET 1 and 2 trials, 1203 highly treatment-experienced patients were randomized to etravirine...

Behavioral interventions for improving dual-method contraceptive use

2014

Background: Dual-method contraception refers to using condoms as well as another modern method of contraception. The latter (usually non-barrier) method is commonly hormonal (e.g., oral contraceptives) or a non-hormonal intrauterine...

Duration of ruptured membranes and vertical transmission of HIV-1: A meta-analysis from 15 prospective cohort studies

2001

Objective: To test the a priori hypothesis that longer duration of ruptured membranes is associated with increased risk of vertical transmission of HIV. Design: The relationship between duration of ruptured...

Nystatin prophylaxis and treatment in severely immunodepressed patients

2002

BACKGROUND: Nystatin is sometimes used prophylactically in patients with severe immunodeficiency or in the treatment of fungal infection in such patients, although the effect seems to be equivocal. OBJECTIVES: To...

Simultaneous prevention of unintended pregnancy and STIs: A challenging compromise

2014

BACKGROUND: Unintended pregnancy and sexually transmitted infections (STIs) are the major negative consequences of unsafe sex. Both are common and have long-term social and health consequences. Barrier methods of contraception...

Modeling the cost-effectiveness of HIV treatment: how to buy the most ‘health’ when resources are limited

2013

PURPOSE OF REVIEW: To summarize recent cost-effectiveness analyses (CEAs) that evaluate optimal treatment strategies for persons living with HIV/AIDS (PLWHA). RECENT FINDINGS: Efforts to attain universal coverage of current treatment...

Family-centred approaches to the prevention of mother to child transmission of HIV

2010

Prevention of mother to child transmission (PMTCT) programmes have traditionally been narrow in scope, targeting biomedical interventions during the perinatal period, rather than considering HIV as a family disease. This...

Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs

2001

A meta-analysis was conducted on studies using a treatment-comparison group design to evaluate HIV/AIDS risk-reduction interventions for clients enrolled in drug abuse treatment programs. Overall, the interventions studied were found...

Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: A meta-analysis of randomized clinical trials

2001

Purpose: A meta-analysis of randomized controlled trials (RCTs) was performed to evaluate effectiveness and tolerability of triple antiretroviral therapy regimens in HIV-infected patients. Method: RCTs including the nonnucleoside reverse transcriptase...

Review of drug interactions with telaprevir and antiretrovirals

2013

HCV infection is a major cause of mortality worldwide. HCV-related deaths also represent a leading cause of mortality in HIV-coinfected individuals. Telaprevir is an NS3/4A protease inhibitor approved for the...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!